Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals announced positive results from a phase 3 study of Repretinib in gastrointestinal stromal tumors.
Read Source